Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma

Ju Youn Lee; Michail Schizas; Felipe C. Geyer; Pier Selenica; Salvatore Piscuoglio; Rita A. Sakr; Charlotte K.Y. Ng; Jose V. Scarpa Carniello; Russell Towers; Dilip D. Giri; Victor P. de Andrade; Anastasios D. Papanastasiou; Agnes Viale; Reuben S. Harris; David B. Solit; Britta Weigelt; Jorge S. Reis-Filho; Tari A. King

doi:10.1158/1078-0432.CCR-18-1103

Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma

Ju Youn Lee, Michail Schizas, Felipe C. Geyer, Pier Selenica, Salvatore Piscuoglio, Rita A. Sakr, Charlotte K.Y. Ng, Jose V. Scarpa Carniello, Russell Towers, Dilip D. Giri, Victor P. de Andrade, Anastasios D. Papanastasiou, Agnes Viale, Reuben S. Harris, David B. Solit, Britta Weigelt, Jorge S. Reis-Filho, Tari A. King

Molecular Biology (BMBB)

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

PURPOSE: Lobular carcinoma in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers. Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods.

RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases.

CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.

Original language	English (US)
Pages (from-to)	674-686
Number of pages	13
Journal	Clinical Cancer Research
Volume	25
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-1103
State	Published - Jan 15 2019

Bibliographical note

Funding Information:
J.S. Reis-Filho is funded in part by the Breast Cancer Research Foundation. S. Piscuoglio is funded by the Swiss National Science Foundation (Ambizione grant number PZ00P3_168165). R.S. Harris is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute. Research reported in this publication was supported in part by 2009 Komen Career Catalyst Award (T.A. King), 2012 Komen Investigator Initiated Research Award (T.A. King), Susan G. Komen for the Cure, and by a Cancer Center Support Grant of the NIH/NCI (grant no. P30CA008748).

Publisher Copyright:
© 2018 American Association for Cancer Research.

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/1078-0432.CCR-18-1103

Find It

Find It at U of M Libraries

Cite this

Lee, J. Y., Schizas, M., Geyer, F. C., Selenica, P., Piscuoglio, S., Sakr, R. A., Ng, C. K. Y., Scarpa Carniello, J. V., Towers, R., Giri, D. D., de Andrade, V. P., Papanastasiou, A. D., Viale, A., Harris, R. S., Solit, D. B., Weigelt, B., Reis-Filho, J. S., & King, T. A. (2019). Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma. Clinical Cancer Research, 25(2), 674-686. https://doi.org/10.1158/1078-0432.CCR-18-1103

Lee, JY, Schizas, M, Geyer, FC, Selenica, P, Piscuoglio, S, Sakr, RA, Ng, CKY, Scarpa Carniello, JV, Towers, R, Giri, DD, de Andrade, VP, Papanastasiou, AD, Viale, A, Harris, RS, Solit, DB, Weigelt, B, Reis-Filho, JS & King, TA 2019, 'Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma', Clinical Cancer Research, vol. 25, no. 2, pp. 674-686. https://doi.org/10.1158/1078-0432.CCR-18-1103

@article{8278d0ec2ad74bc297e284e7c1403bf2,

title = "Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma",

abstract = "PURPOSE: Lobular carcinoma in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers. Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods. RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases. CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.",

author = "Lee, {Ju Youn} and Michail Schizas and Geyer, {Felipe C.} and Pier Selenica and Salvatore Piscuoglio and Sakr, {Rita A.} and Ng, {Charlotte K.Y.} and {Scarpa Carniello}, {Jose V.} and Russell Towers and Giri, {Dilip D.} and {de Andrade}, {Victor P.} and Papanastasiou, {Anastasios D.} and Agnes Viale and Harris, {Reuben S.} and Solit, {David B.} and Britta Weigelt and Reis-Filho, {Jorge S.} and King, {Tari A.}",

note = "Funding Information: J.S. Reis-Filho is funded in part by the Breast Cancer Research Foundation. S. Piscuoglio is funded by the Swiss National Science Foundation (Ambizione grant number PZ00P3_168165). R.S. Harris is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute. Research reported in this publication was supported in part by 2009 Komen Career Catalyst Award (T.A. King), 2012 Komen Investigator Initiated Research Award (T.A. King), Susan G. Komen for the Cure, and by a Cancer Center Support Grant of the NIH/NCI (grant no. P30CA008748). Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2019",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-18-1103",

language = "English (US)",

volume = "25",

pages = "674--686",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma

AU - Lee, Ju Youn

AU - Schizas, Michail

AU - Geyer, Felipe C.

AU - Selenica, Pier

AU - Piscuoglio, Salvatore

AU - Sakr, Rita A.

AU - Ng, Charlotte K.Y.

AU - Scarpa Carniello, Jose V.

AU - Towers, Russell

AU - Giri, Dilip D.

AU - de Andrade, Victor P.

AU - Papanastasiou, Anastasios D.

AU - Viale, Agnes

AU - Harris, Reuben S.

AU - Solit, David B.

AU - Weigelt, Britta

AU - Reis-Filho, Jorge S.

AU - King, Tari A.

N1 - Funding Information: J.S. Reis-Filho is funded in part by the Breast Cancer Research Foundation. S. Piscuoglio is funded by the Swiss National Science Foundation (Ambizione grant number PZ00P3_168165). R.S. Harris is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute. Research reported in this publication was supported in part by 2009 Komen Career Catalyst Award (T.A. King), 2012 Komen Investigator Initiated Research Award (T.A. King), Susan G. Komen for the Cure, and by a Cancer Center Support Grant of the NIH/NCI (grant no. P30CA008748). Publisher Copyright: © 2018 American Association for Cancer Research.

PY - 2019/1/15

Y1 - 2019/1/15

N2 - PURPOSE: Lobular carcinoma in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers. Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods. RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases. CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.

AB - PURPOSE: Lobular carcinoma in situ (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers. Experimental Design: We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas in situ (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational methods. RESULTS: WES of 43 LCIS lesions revealed a genomic profile similar to that previously reported for ILCs, with CDH1 mutations present in 81% of the lesions. Forty-two percent (18/43) of LCIS were found to be clonally related to synchronous DCIS and/or ILCs, with clonal evolutionary patterns indicative of clonal selection and/or parallel/branched progression. Intralesion genetic heterogeneity was higher among LCIS clonally related to DCIS/ILC than in those nonclonally related to DCIS/ILC. A shift from aging to APOBEC-related mutational processes was observed in the progression from LCIS to DCIS and/or ILC in a subset of cases. CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a nonobligate precursor of breast cancer. Intralesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions.

UR - http://www.scopus.com/inward/record.url?scp=85060045931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060045931&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1103

DO - 10.1158/1078-0432.CCR-18-1103

M3 - Article

C2 - 30185420

AN - SCOPUS:85060045931

SN - 1078-0432

VL - 25

SP - 674

EP - 686

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this